Oxocoumarin and barbituric acid derivates, their preparation and their use as ligand inhibitors of corticotropin-releasing factor (crf) and/or a crf-binding protein complex

摘要

Ligand inhibitors for increasing levels of free corticotropin-releasing factor (CRF) in the brain are disclosed. Such ligand inhibitors cause release of CRF from the CRF/CRF-bind protein complex. Administration of the ligand inhibitors provide improvement in learning and memory, result in decreased food intake and/or provide treatment for diseases associated with low levels of CRF in the brain, notably Alzheimer's disease.